



RESEARCH ARTICLE

Investigation of the genotype III to genotype I shift in Japanese encephalitis virus and the impact on human cases

Na Han^{3,4}, James Adams², Wei Fang², Si-Qing Liu², Simon Rayner^{1,2}✉

1. Department of Medical Genetics, Oslo University Hospital, Oslo 0271, Norway
2. State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
3. State Key Laboratory for Infectious Diseases Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
4. Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China

Japanese encephalitis is a mosquito borne disease and is the leading cause of viral encephalitis in the Asia-Pacific area. The causative agent, Japanese encephalitis virus (JEV) can be phylogenetically classified into five genotypes based on nucleotide sequence. In recent years, genotype I (GI) has displaced genotype III (GIII) as the dominant lineage, but the mechanisms behind this displacement event requires elucidation. In an earlier study, we compared host variation over time between the two genotypes and observed that GI appears to have evolved to achieve more efficient infection in hosts in the replication cycle, with the tradeoff of reduced infectivity in secondary hosts such as humans. To further investigate this phenomenon, we collected JEV surveillance data on human cases and, together with sequence data, and generated genotype/case profiles from seven Asia-Pacific countries and regions to characterize the GI/GIII displacement event. We found that, when comprehensive and consistent vaccination and surveillance data was available, and the GIII to GI shift occurred within a well-defined time period, there was a statistically significant drop in JEV human cases. Our findings provide further support for the argument that GI is less effective in infecting humans, who represent a dead end host. However, experimental investigation is necessary to confirm this hypothesis. The study highlights the value of alternative approaches to investigation of epidemics, as well as the importance of effective data collection for disease surveillance and control.

KEYWORDS flavivirus; Japanese encephalitis virus (JEV); bioinformatics; epidemiology; lineage replacement

INTRODUCTION

Japanese encephalitis is a mosquito borne disease and is the leading cause of viral encephalitis in the Asia-Pacific area, with annual cases recently estimated to be ~68,000 with a 10% to 15% mortality rate (Tsai, 2000;

Campbell et al., 2011). JEV is transmitted in a zoonotic cycle, with mosquitoes transmitting the virus through bites, and wading birds and pigs serving as primary wild and domestic amplifying hosts respectively. Phylogenetic investigations of sequences from isolates indicate the presence of five genotypes, GI to GV, with the majority of cases associated with GI and GIII. Until the 1990s, GIII was the dominant genotype associated with outbreaks and other genotypes only occurred sporadically. However, in the last 20 years, evidence indicates that GI has almost completely displaced GIII in all regions and is now the dominant genotype.

In an earlier study (Pan et al., 2011), we showed that

Received: 30 June 2015, Accepted: 13 August 2015

Published online: 18 August 2015

✉ Correspondence:

Phone: +86-27-87199895/+47-638-06657, Fax: +86-27-87199895,

Email: s.rayner@wh.iov.cn, simon.rayner@medisin.uio.no

ORCID: 0000-0001-8703-9140

this GIII/GI displacement event was accompanied by an order of magnitude increase in the genetic diversity of GI relative to GIII. In a more recent report (Han et al., 2014), we collected all publically available sequences collected from JEV cases and investigated variation in host composition over time and by genotype. Our findings suggested that GI gained dominance by achieving a more focused host range. In particular, (i) while number of GI isolates associated with mosquitoes and pigs increased over time, consistent with the displacement event, human cases remained predominantly associated with GIII and (ii) despite the increase in number of mosquito isolates, the diversity of mosquito types was significantly narrower in GI. This result was also consistent with an experimental study by Schuh *et al.* (Schuh et al., 2014) which observed higher infectivity for GI in mosquito cells.

In this study, we collected surveillance data on JEV outbreaks spanning the time period over which the GI/GIII displacement event occurred and investigated the relationship between human cases, vaccination, and identified GI and GIII cases (via sequencing and phylogenetic analysis of isolates). In regions with comprehensive record keeping and vaccination programs we observed a strong inverse correlation between human cases and GI, further supporting the argument that GI gained dominance by accommodating a narrower host range. These findings highlight the value of comprehensive surveillance data and analytical techniques to complement more experimental methods for the investigation of infectious disease.

MATERIALS AND METHODS

Consolidation of surveillance and vaccination data

To obtain a regional summary of the change in the prevalence of JEV and vaccination coverage over time in epidemic and endemic regions in Asia and the Pacific, we performed an online search for publications related to JEV surveillance and vaccination programs, and contacted regional health authorities to gain access to and assistance in interpreting local surveillance data. The downloaded sources comprised published research with entries in PubMed as well as World Health Organization (WHO) Health Bulletins, WHO Weekly Epidemiological Records and National Annual Health Statistics (MHLWJ, 2011; KCDCP, 2012; TMPH, 2012). The reports were reviewed to determine an annual estimate of JEV for each country or region in terms of vaccination coverage, number of cases and number of fatalities. Where possible, preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines were adopted in an attempt to identify and account for biasing due to sampling

and detection methods (Liberati et al., 2009). In particular, only reports that supplied number of cases and fatalities supplied by local or regional health authorities, and within clearly defined date ranges, were selected. Several of the Chinese papers did not have PubMed entries, and these are listed in [supplementary Table S1](#). The isolation date and location information of sequences were used to determine the presence and absence of each genotype in individual regions over time. Based on this we generated datasets for Mainland China, Chinese Taiwan, India, Japan, Democratic Republic of Korea (South Korea), Thailand and Viet Nam between 1980 to 2010 for further analysis.

Sequence datasets

The sequence datasets described in (Han et al., 2014) were used to generate a profile of the presence of GI and GIII by region over time. Briefly, the data comprised 347 GI and 275 GIII isolates retrieved from the GenBank database (<http://www.ncbi.nlm.nih.gov/>) with vaccine or derivative strains, in vitro cultured isolates and sequences containing significant numbers of ambiguous non-standard nucleotide or amino acid characters excluded. The sequences were isolated from a variety of hosts (mosquitoes, midges, bats, pigs, horses and humans) with collection dates from 1949 to 2009 and a geographic distribution spanning Mainland China, Chinese Taiwan, India, Japan, South Korea, Thailand and Viet Nam. The genotype of each isolate was identified by phylogenetic analysis. A full list of sequences and their background information, including identified genotype, is available in the supplementary information in (Han et al., 2014).

Investigation of correlation between genotype and surveillance data

For Mainland China, Chinese Taiwan, India, Japan, South Korea, Thailand and Viet Nam there was sufficient genotype information to investigate the relationship between genotype presence and JEV case data. In these cases, each region was investigated by χ^2 test to investigate significant variations in cases and fatalities in the presence and absence of vaccination and in the presence and absence of the GI and GIII genotypes.

RESULTS

Association between vaccination, JE human cases and genotype shift.

Datasets for Mainland China ([Figure 1](#)), Chinese Taiwan ([Figure 2](#)), India ([Figure 3](#)), Japan ([Figure 4](#)), South Korea ([Figure 5](#)), Thailand ([Figure 6](#)) and Viet Nam ([Figure 7](#)) were generated as described in the Materials and Methods. Based on the available data, these regions were summarized as follows: Mainland China,




Figure 1. JEV situation in Mainland China. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, mortality rate; vaccination coverage. For GI and GIII occurrence, the top row corresponds to GI, the bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolates respectively were collected for that year. Dark green and dark blue indicate no isolates were collected for that year. The number of human cases has gradually decreased over the time period due to a progressively more comprehensive national vaccination program, but specific details about the percentage of coverage are not available so details are shown only for Guangxi province.




Figure 2. JEV situation in Chinese Taiwan. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, mortality rate; vaccination coverage. For GI and GIII occurrence, top row corresponds to GI, bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolate respectively was collected for that year. Dark green and dark blue indicate no isolates were collected for that year. Taiwan has an effective vaccination and surveillance program that has brought the number of human cases down to a handful a year.




Figure 3. JEV situation in India. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, mortality rate; vaccination coverage. For GI and GIII occurrence, the top row corresponds to GI, the bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolates respectively were collected for that year. Dark green and dark blue indicate no isolates were collected for that year. Vaccination was introduced in recent years, but is not comprehensive.




Figure 4. JEV situation in Japan. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, mortality rate; vaccination coverage. For GI and GIII occurrence, the top row corresponds to GI, the bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolates respectively were collected for that year. Dark green and dark blue indicate no isolates were collected for that year. Japan has an effective vaccination and surveillance program but the number of cases remained between 20 to 60 annually until the early 1990s when there was a dramatic drop that coincided with the GIII to GI shift ($p = 0.047$).




Figure 5. JEV situation in South Korea. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, mortality rate; vaccination coverage. For GI and GIII occurrence, the top row corresponds to GI, the bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolates respectively were collected for that year. Dark green and dark blue indicate no isolates were collected for that year. South Korea has an effective vaccination and surveillance program that has brought number of human cases down to one or two a year and there is no measurable difference in human cases before and after the GIII to GI displacement event.




Figure 6. JEV situation in Thailand. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, fatality rate; vaccination coverage. For GI and GIII occurrence, the top row corresponds to GI, the bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolates respectively were collected for that year. Dark green and dark blue indicate no isolates were collected for that year. The upper graph shows isolates for Thailand, the lower graph shows isolates for Viet Nam; as insufficient data was available for Thailand, Viet Nam was used. The annual number of human cases has remained in the 100s despite a comprehensive and continuous vaccination campaign. However, the mortality rate has decreased significantly since GI became the dominant lineage in the region ($p < 2.2 \times 10^{-16}$).




Figure 7. JEV situation in Viet Nam. From top to bottom: GI and GIII occurrence; number of human cases; number of deaths, mortality rate; vaccination coverage. For GI and GIII occurrence, the top row corresponds to GI, the bottom row corresponds to GIII. Light green and light blue squares indicate that GI and GIII isolates respectively were collected for that year. Dark green and dark blue indicate no isolates were collected for that year. Limited surveillance data is available over the period to determine the impact of the GI to GIII shift.

GI and GIII present over the course of the data, partial but increasing vaccination over the date range but limited details, limited surveillance of insect vectors and arboviruses before 2003 (Liu et al., 2006); Chinese Taiwan, introduction of GI around 2008, high vaccination coverage from 1980 to 2010 (Jan et al., 2000; Huang et al., 2010; Chen et al., 2011). India, introduction of GI around 2009, low vaccination (Umenai et al., 1985; Chakraborty et al., 1987; Angami et al., 1989; George et al., 1990; Mukherjee et al., 1991; Vajpayee et al., 1991; Kar et al., 1992; Vajpayee et al., 1992; Prasad et al., 1993; Thakare et al., 1999; Rao et al., 2000; Chattopadhyay, 2001; Kaur et al., 2002; Potula et al., 2003; Kabilan et al., 2004; Phukan et al., 2004; Mudur, 2005; Parida et al., 2006; Dhillon and Raina, 2008; Saxena et al., 2009; Sarkar et al., 2012; Sarkari et al., 2012; Tiwari et al., 2012). Japan, introduction of GI and displacement of GIII 1991 to 1992, nationwide vaccination 1967 to 2004 (Ma et al., 2003; Kuwayama et al., 2005; Saito et al., 2007; Arai et al., 2008; Tang et al., 2010; MHLWJ, 2011; Obara et al., 2011; Konishi et al., 2012). South Korea, introduction of GI and displacement of GIII 1991 to 1994, nationwide vaccination program introduced in 1985 (Sohn, 2000; Yun et al., 2010; Takhampunya et al., 2011; KCDCP, 2012; Seo et al., 2013). Thailand, limited genotype information, but reported genotype shift in late 1990s, nationwide vaccination program introduced early 1990s (Henrich et al., 2003; Nitatpattana et al., 2008; Olsen et al., 2010; TMPH, 2012). Viet Nam, No GIII cases reported since 2005, limited vaccination data available (Nga et al., 2004; Le et al., 2010; Yen et al., 2010; Ho Dang Trung et al., 2012). For each dataset, to deconvolute the effect of vaccination on human cases, we selected time frames where there was a genotype displacement and there was either no vaccination or comprehensive vaccination in a region.

For India the surveillance data fails to clearly distinguish between JEV and acute encephalitis syndrome (AES) to make reliable estimates except for recent years (NVBDPC, 2012). In Japan, due to some adverse reactions in 2004, vaccination rates dropped between 2005 and 2009, but were resumed in 2010. For Mainland China, only a single JEV isolate was collected between 1990 and 2001. There are limited sequences available for Thailand and limited surveillance data for Viet Nam so, given the geographical proximity of the two countries, we combined the genotype data for Viet Nam with surveillance data for Thailand to estimate the JEV situation in Thailand. Based on this information, we performed a χ^2 test on human case data for (i) Mainland China for 1979 to 1996 compared to 2002 to 2010, (ii) Chinese Taiwan for 2006 and 2008 compared to 2009 to 2011, (iii) India for 2006 and 2008 compared to 2009 to 2011, (iv) Japan for 1982 to 1991 compared to 1992 to 2004, (v)

South Korea for 1982 to 1994 compared to 1995 to 2010 and (vi) Thailand for 1995 to 2003 compared to 2004 to 2009. No statistical test was performed for Viet Nam.

For Chinese Taiwan and India there was no statistically significant change observed in human cases before and after the genotype shift event. For Chinese Taiwan, the genotype shift occurred relatively recently (relative to available surveillance data) around 2005 to 2008 and so there is insufficient post shift data for comparison. For India, there is limited reliable surveillance data available as there is no clear distinction between JEV cases and other encephalitis cases. For Japan and Thailand there were significant decreases in the mortality rate after the genotype shift event ($p = 0.047$ and $p < 2.2 \times 10^{-16}$ respectively). For South Korea, there was also a statistically significant difference between the two time intervals ($p = 0.014$), that indicated there were more cases after the shift event, but this was due to a single outbreak that occurred in 2010 that dominated the dataset, which is primarily comprised of one or two cases/year for the last 25 years. For Mainland China, there was a significant difference between mortality rates for the two time frames, consistent with the gradual increase in vaccination coverage that has occurred over the last thirty years (Liu et al., 2006).

DISCUSSION

Japanese encephalitis has a major impact on public health in the Asia-Pacific area. While effective vaccines exist, they are based on GIII, which was the dominant genotype at the time, and the observation that GI was gradually displacing GIII raised concerns regarding the continuing efficacy of the vaccine. There have been many publications related to GIII displacement in various countries and regions, e.g. (Nga et al., 2004; Nitatpattana et al., 2008; Chen et al., 2011; Fulmali et al., 2011), but these have focused on reporting the displacement, rather than investigating the cause. While lineage displacement is a common event, JEV is distinct insofar as, compared to many other viruses, it is highly conserved between genotypes, and there is less than 1% variation between GI and GIII. Thus, understanding the mechanisms driving this displacement could help to determine the significance and impact of future events.

In this study, we have attempted to build a comprehensive dataset describing the JEV GIII/GI displacement event from a number of different perspectives. In our earlier work, we consolidated all sequence data collected from across JEV incidence regions and investigated how host composition varied over the course of the genotype displacement event. Based on this, we were able to identify significant differences in the host range of the two genotypes. In particular, the majority of se-

quence isolates from human cases remained associated with GIII, suggesting that GI might be less effective at infecting humans. In this work, we built on these results and examined whether this difference was also visible in surveillance data. We used sequence data to build a GI/GIII presence profile for each region and combined this with vaccination and human case data collected at a regional scale in an attempt to identify differences between “before” and “after” GIII to GI shift events. In this way we have created a comprehensive dataset describing the impact on JEV in the Asia-Pacific area over the course of the last thirty years. For regions where there was comprehensive data available, and a well-defined genotype shift there was a distinct and statistically significant drop in human cases when the shift from GIII to GI occurred. However, in the majority of cases, there was insufficient data to support this time of analysis or to achieve statistical significance.

One possible criticism of our analysis of surveillance data is the problem of sampling bias, including under-reporting of human cases, difference in detection methods, variation in testing over time and the question of what defines a true JE case. For this reason, we deliberately restricted our analysis to comparison of datasets within each country or region, over a limited time frame (and over a period for which vaccination was either comprehensive or non-existent) and only considered more recent data. In fact, similar concerns can be raised at widely quoted estimates of global incidence of JEV which are based on the same data sources (Burke and Leake, 1988; Nishijima et al., 2012) and here at least we are able to avoid bias that might be present in the studies, introduced by regional differences in surveillance techniques, as we are only performing comparison of data collected from a single country or region. Additionally, other factors such as the challenge of accurate diagnosis of JEV (Solomon et al., 2008), variation and advances in diagnostic methods (Shrivastva et al., 2008; Dong et al., 2012), and climatic changes (Johansson et al., 2009; Le Flohic et al., 2013) could also confound this analysis, and could also be factors in the observed changes. However, for these factors, we would expect either a gradual change (as new technology is gradually adopted) or periodic or random fluctuations (in the case of climatic factors). In the case of the data from Japan, the genotype replacement occurred within a well-defined time interval, there was no changes in diagnostic methods and was accompanied by an order of magnitude drop in the number of recorded cases.

While the apparent reduced infection efficacy in humans implies there may be a reduced probability of human infections, this is counterbalanced by the higher infection rates in pigs and mosquitoes, which are primarily responsible for the viral replication cycle. The pre-

dicted increase in infection rates indicates there will be higher numbers of infected mosquitoes, which suggests the higher probability of spillover could compensate for a probability of lower infection. This highlights the necessity of continuing comprehensive vaccination and prevention strategies. Our approach demonstrates the value of combining and analyzing different data types to describe the evolution of a virus and the subsequent impact on the environment, as well as the value of comprehensive surveillance data and case reports. Nevertheless, our analysis hypothesizes rather than concludes an association between genotype shift and drop in number of human cases. Thus, experimental investigation and additional data collection are needed to further confirm whether there are distinct differences between GI and GIII in terms of in terms of symptoms, severity of infection and mortality rates.

ACKNOWLEDGMENTS

This work was supported by NSFC grant number 81371810.

COMPLIANCE WITH ETHICS GUIDELINES

The authors declare that they have no conflict of interest. This article does not contain any studies with human or animal subjects performed by any of the authors.

AUTHOR CONTRIBUTIONS

NH and SR designed the analysis. NH, SR, WF, SLQ & JA carried out the analysis and interpretation of results, NH, SR & JA wrote the paper. All authors read and approved the final manuscript.

Supplementary figures/tables are available on the website of *Virologica Sinica*: www.virosin.org; link.springer.com/journal/12250.

REFERENCES

- Angami K, Chakravarty SK, Das MS, Chakraborty MS, Mukherjee KK. 1989. Seroepidemiological study of Japanese encephalitis in Dimapur, Nagaland. *J Commun Dis*, 21: 87–95.
- Arai S, Matsunaga Y, Takasaki T, Tanaka-Taya K, Taniguchi K, Okabe N, Kurane I. 2008. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. *Jpn J Infect Dis*, 61: 333–338.
- Burke DS, Leake CJ. 1988. Japanese encephalitis. In: *The Arboviruses: epidemiology and ecology*. T.P. Monath (ed.). Boca Raton: CRC Press, pp. 63–92.
- Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, Ginsburg AS. 2011. Estimated global incidence of Japanese encephalitis:

- a systematic review. *Bull World Health Organ*, 89: 766–774, 774A–774E.
- Chakraborty AK, Chakravarti SK, Chakravarty MS. 1987. Outbreak of Japanese encephalitis in two districts of Assam during 1980: some epidemiological features. *Indian J Public Health*, 31: 5–11.
- Chattopadhyay UK. 2001. A study on the status of Japanese encephalitis infection in Arunachal Pradesh. *J Commun Dis*, 33: 261–265.
- Chen YY, Fan YC, Tu WC, Chang RY, Shih CC, Lu IH, Chien MS, Lee WC, Chen TH, Chang GJ, Chiou SS. 2011. Japanese encephalitis virus genotype replacement, Taiwan, 2009–2010. *Emerg Infect Dis*, 17: 2354–2356.
- Dhillon GP, Raina VK. 2008. Epidemiology of Japanese encephalitis in context with Indian scenario. *J Indian Med Assoc*, 106: 660–663.
- Dong D, Fu SH, Wang LH, Lv Z, Li TY, Liang GD. 2012. Simultaneous detection of three arboviruses using a triplex RT-PCR: enzyme hybridization assay. *Virolog Sin*, 27: 179–186.
- Fulmali PV, Sapkal GN, Athawale S, Gore MM, Mishra AC, Bondre VP. 2011. Introduction of Japanese encephalitis virus genotype I, India. *Emerg Infect Dis*, 17: 319–321.
- George S, Yergolkar PN, Kamala H, Kamala CS. 1990. Outbreak of encephalitis in Bellary District of Karnataka & adjoining areas of Andhra Pradesh. *Indian J Med Res*, 91: 328–330.
- Han N, Adams J, Chen P, Guo ZY, Zhong XF, Fang W, Li N, Wen L, Tao XY, Yuan ZM, Rayner S. 2014. Comparison of genotypes I and III in Japanese encephalitis virus reveals distinct differences in their genetic and host diversity. *J Virol*, 88: 11469–11479.
- Henrich TJ, Hutchaleelaha S, Jiwariyavej V, Barbazan P, Nitatpattana N, Yoksan S, Gonzalez JP. 2003. Geographic dynamics of viral encephalitis in Thailand. *Microbes Infect*, 5: 603–611.
- Ho Dang Trung N, Le Thi Phuong T, Wolbers M, Nguyen Van Minh H, Nguyen Thanh V, Van MP, Thieu NT, Van TL, Song DT, Thi PL, Thi Phuong TN, Van CB, Tang V, Ngoc Anh TH, Nguyen D, Trung TP, Thi Nam LN, Kiem HT, Thi Thanh TN, Campbell J, Caws M, Day J, de Jong MD, Van Vinh CN, Van Doorn HR, Tinh HT, Farrar J, Schultz C. 2012. Aetiologies of central nervous system infection in Viet Nam: a prospective provincial hospital-based descriptive surveillance study. *PLoS One*, 7: e37825.
- Huang JH, Lin TH, Teng HJ, Su CL, Tsai KH, Lu LC, Lin C, Yang CF, Chang SF, Liao TL, Yu SK, Cheng CH, Chang MC, Hu HC, Shu PY. 2010. Molecular epidemiology of Japanese encephalitis virus, Taiwan. *Emerg Infect Dis*, 16: 876–878.
- Jan LR, Yueh YY, Wu YC, Horng CB, Wang GR. 2000. Genetic variation of Japanese encephalitis virus in Taiwan. *Am J Trop Med Hyg*, 62: 446–452.
- Johansson MA, Cummings DA, Glass GE. 2009. Multiyear climate variability and dengue—El Niño southern oscillation, weather, and dengue incidence in Puerto Rico, Mexico, and Thailand: a longitudinal data analysis. *PLoS Med*, 6: e1000168.
- Kabilan L, Vrati S, Ramesh S, Srinivasan S, Appaiahgari MB, Arunachalam N, Thenmozhi V, Kumaravel SM, Samuel PP, Rajendran R. 2004. Japanese encephalitis virus (JEV) is an important cause of encephalitis among children in Cuddalore district, Tamil Nadu, India. *J Clin Virol*, 31: 153–159.
- Kar NJ, Bora D, Sharma RC, Bhattacharjee J, Datta KK, Sharma RS. 1992. Epidemiological profile of Japanese encephalitis in Gorakhpur district, Uttar Pradesh, 1982–1988. *J Commun Dis*, 24: 145–149.
- Kaur R, Agarwal CS, Das D. 2002. An investigation into the JE epidemic of 2000 in Upper Assam—a perspective study. *J Commun Dis*, 34: 135–145.
- KCDCP. 2012. (Korean Centre for Disease Control & Prevention). *Public Health Weekly Report*, 5: 491.
- Konishi E, Kitai Y, Nishimura K, Harada S. 2012. Follow-up survey of Japanese encephalitis virus infection in Kumamoto Prefecture, South-West Japan: status during 2009–2011. *Jpn J Infect Dis*, 65: 448–450.
- Kuwayama M, Ito M, Takao S, Shimazu Y, Fukuda S, Miyazaki K, Kurane I, Takasaki T. 2005. Japanese encephalitis virus in meningitis patients, Japan. *Emerg Infect Dis*, 11: 471–473.
- Le Flohic G, Porphyre V, Barbazan P, Gonzalez JP. 2013. Review of climate, landscape, and viral genetics as drivers of the Japanese encephalitis virus ecology. *PLoS Negl Trop Dis*, 7: e2208.
- Le VT, Phan TQ, Do QH, Nguyen BH, Lam QB, Bach V, Truong H, Tran TH, Nguyen V, Tran T, Vo M, Tran VT, Schultsz C, Farrar J, van Doorn HR, de Jong MD. 2010. Viral etiology of encephalitis in children in southern Vietnam: results of a one-year prospective descriptive study. *PLoS Negl Trop Dis*, 4: e854.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*, 6: e1000100.
- Liu W, Clemens JD, Yang JY, Xu ZY. 2006. Immunization against Japanese encephalitis in China: a policy analysis. *Vaccine*, 24: 5178–5182.
- Ma SP, Yoshida Y, Makino Y, Tadano M, Ono T, Ogawa M. 2003. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. *Am J Trop Med Hyg*, 69: 151–154.
- MHLWJ. 2011. (Ministry of Health, Labour and Welfare. Japan.) Current status of Japanese encephalitis vaccination. (In Japanese)
- Mudur G. 2005. Japanese encephalitis outbreak kills 1300 children in India. *BMJ*, 331: 1288.
- Mukherjee KK, Chakravarti SK, Mukherjee MK, De PN, Chatterjee S, Chatterjee P, Chakraborty MS. 1991. Recurrent outbreaks of Japanese encephalitis in Nagaland (1985–1989)—a seroepidemiological study. *J Commun Dis*, 23: 11–17.
- Nga PT, del Carmen Parquet M, Cuong VD, Ma SP, Hasebe F, Inoue S, Makino Y, Takagi M, Nam VS, Morita K. 2004. Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: implications for frequent introductions of JEV from Southeast Asia to East Asia. *J Gen Virol*, 85: 1625–1631.
- Nishijima N, Marusawa H, Ueda Y, Takahashi K, Nasu A, Osaki Y, Kou T, Yazumi S, Fujiwara T, Tsuchiya S, Shimizu K, Uemoto S, Chiba T. 2012. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. *PLoS One*, 7: e35052.
- Nitatpattana N, Dubot-Peres A, Gouilh MA, Souris M, Barbazan P, Yoksan S, de Lamballerie X, Gonzalez JP. 2008. Change in Japanese Encephalitis Virus Distribution, Thailand. *Emerg Infect Dis*, 14: 1762–1765.
- NVBDCP. 2012. (India Ministry of Health & Family Welfare). Japanese Encephalitis cases 2008–2010.
- Obara M, Yamauchi T, Watanabe M, Hasegawa S, Ueda Y, Matsuno K, Iwai M, Horimoto E, Kurata T, Takizawa T, Kariwa H, Takashima I. 2011. Continuity and change of Japanese encephalitis virus in Toyama Prefecture, Japan. *Am J Trop Med Hyg*, 84: 695–708.
- Olsen SJ, Supawat K, Campbell AP, Anantapreecha S, Liamswan S, Tunlayadechanont S, Visudtibhan A, Lupthikulthum S, Dhiravibulya K, Viriyavejakul A, Vasiknanonte P, Rajborirug K, Watanaveeradej V, Nabangchang C, Laven J, Kosoy O, Panella A, Ellis C, Henchaichon S, Khetsuriani N, Powers AM, Dowell SF, Fischer M. 2010. Japanese encephalitis virus remains an important cause of encephalitis in Thailand. *Int J Infect Dis*, 14: e888–892.
- Pan XL, Liu H, Wang HY, Fu SH, Liu HZ, Zhang HL, Li MH,

- Gao XY, Wang JL, Sun XH. 2011. Emergence of Genotype I of Japanese Encephalitis Virus as the Dominant Genotype in Asia. *J Virol*, 85: 9847–9853.
- Parida M, Dash PK, Tripathi NK, Ambuj, Sannarangaiah S, Saxena P, Agarwal S, Sahni AK, Singh SP, Rathi AK, Bhargava R, Abhyankar A, Verma SK, Rao PV, Sekhar K. 2006. Japanese Encephalitis Outbreak, India, 2005. *Emerg Infect Dis*, 12: 1427–1430.
- Phukan AC, Borah PK, Mahanta J. 2004. Japanese encephalitis in Assam, northeast India. *Southeast Asian J Trop Med Public Health*, 35: 618–622.
- Potluri R, Badrinath S, Srinivasan S. 2003. Japanese encephalitis in and around Pondicherry, South India: a clinical appraisal and prognostic indicators for the outcome. *J Trop Pediatr*, 49: 48–53.
- Prasad SR, Kumar V, Marwaha RK, Batra KL, Rath RK, Pal SR. 1993. An epidemic of encephalitis in Haryana: serological evidence of Japanese encephalitis in a few patients. *Indian Pediatr*, 30: 905–910.
- Rao JS, Misra SP, Patanayak SK, Rao TV, Das Gupta RK, Thapar BR. 2000. Japanese Encephalitis epidemic in Anantapur district, Andhra Pradesh (October–November, 1999). *J Commun Dis*, 32: 306–312.
- Saito M, Taira K, Itokazu K, Mori N. 2007. Recent change of the antigenicity and genotype of Japanese encephalitis viruses distributed on Okinawa Island, Japan. *Am J Trop Med Hyg*, 77: 737–746.
- Sarkar A, Taraphdar D, Mukhopadhyay SK, Chakrabarti S, Chatterjee S. 2012. Serological and molecular diagnosis of Japanese encephalitis reveals an increasing public health problem in the state of West Bengal, India. *Trans R Soc Trop Med Hyg*, 106: 15–19.
- Sarkari NB, Thacker AK, Barthwal SP, Mishra VK, Prapann S, Srivastava D, Sarkari M. 2012. Japanese encephalitis (JE). Part I: clinical profile of 1,282 adult acute cases of four epidemics. *J Neurol*, 259: 47–57.
- Saxena SK, Mishra N, Saxena R, Singh M, Mathur A. 2009. Trend of Japanese encephalitis in North India: evidence from thirty-eight acute encephalitis cases and appraisal of niceties. *J Infect Dev Ctries*, 3: 517–530.
- Schuh AJ, Ward MJ, Leigh Brown AJ, Barrett AD. 2014. Dynamics of the emergence and establishment of a newly dominant genotype of Japanese encephalitis virus throughout Asia. *J Virol*.
- Seo HJ, Kim HC, Klein TA, Ramey AM, Lee JH, Kyung SG, Park JY, Cho YS, Cho IS, Yeh JY. 2013. Molecular Detection and Genotyping of Japanese Encephalitis Virus in Mosquitoes during a 2010 Outbreak in the Republic of Korea. *PLoS One*, 8: e55165.
- Shrivastava A, Tripathi NK, Parida M, Dash PK, Jana AM, Lakshmana Rao PV. 2008. Comparison of a dipstick enzyme-linked immunosorbent assay with commercial assays for detection of Japanese encephalitis virus-specific IgM antibodies. *J Postgrad Med*, 54: 181–185.
- Sohn YM. 2000. Japanese encephalitis immunization in South Korea: past, present, and future. *Emerg Infect Dis*, 6: 17–24.
- Solomon T, Thao TT, Lewthwaite P, Ooi MH, Kneen R, Dung NM, White N. 2008. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. *Bull World Health Organ*, 86: 178–186.
- Takhampanya R, Kim HC, Tippayachai B, Kengluetcha A, Klein TA, Lee WJ, Grieco J, Evans BP. 2011. Emergence of Japanese encephalitis virus genotype V in the Republic of Korea. *Virol J*, 8: 449.
- Tang WF, Ogawa M, Eshita Y, Aono H, Makino Y. 2010. Molecular evolution of Japanese encephalitis virus isolates from swine in Oita, Japan during 1980–2009. *Infect Genet Evol*, 10: 329–336.
- Thakare JP, Shenoy SR, Padbidri VS, Rajput CS, Karmarkar DP, Deo SS. 1999. Japanese encephalitis in Sangli district, Maharashtra. *Indian J Med Res*, 109: 165–166.
- Tiwari S, Singh RK, Tiwari R, Dhole TN. 2012. Japanese encephalitis: a review of the Indian perspective. *Braz J Infect Dis*, 16: 564–573.
- TMPH. 2012. (Thai Ministry of Public Health). Thailand Health Profile Report 2008–2010: 171.
- Tsai TF. 2000. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13–15 October 1998. *Vaccine*, 18 Suppl 2: 1–25.
- Umenai T, Krzysko R, Bektimirov TA, Assaad FA. 1985. Japanese encephalitis: current worldwide status. *Bull World Health Organ*, 63: 625–631.
- Vajpayee A, Dey PN, Chakraborty AK, Chakraborty MS. 1992. Study of the outbreak of Japanese encephalitis in Lakhimpur district of Assam in 1989. *J Indian Med Assoc*, 90: 114–115.
- Vajpayee A, Mukherjee MK, Chakraborty AK, Chakraborty MS. 1991. Investigation of an outbreak of Japanese encephalitis in Rourkela City (Orissa) during 1989. *J Commun Dis*, 23: 18–21.
- Yen NT, Duffy MR, Hong NM, Hien NT, Fischer M, Hills SL. 2010. Surveillance for Japanese encephalitis in Vietnam, 1998–2007. *Am J Trop Med Hyg*, 83: 816–819.
- Yun SM, Cho JE, Ju YR, Kim SY, Ryou J, Han MG, Choi WY, Jeong YE. 2010. Molecular epidemiology of Japanese encephalitis virus circulating in South Korea, 1983–2005. *Virol J*, 7: 127.